Cerexa leads with $50 million in first round financing.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Cerexa
|
$50M
|
Frazier Healthcare Ventures, New Leaf Venture Partners |
A spin-off, Cerexa expects to initiate Phase II clinical trials with PPI-0903, a broad-spectrum cephalosporin antibiotic with methicillin-resistant Staphylococcus aureus (MRSA) coverage, in the second half of 2005. |
|
Cerenis Therapeutics
|
$30.5M
|
Sofinnova Partners, HealthCap |
Cerenis has been established with the objective of discovering, developing and commercializing breakthrough HDL-related drugs for the treatment of cardiovascular and metabolic diseases. |
|
Alba Therapeutics
|
$30M
|
SV Life Sciences, Alta Partners |
Alba's lead molecule, AT-1001, is targeted toward the treatment of Celiac Disease and Type 1 Diabetes and is in the final stages of pre-human testing. |
|
Protez Pharmaceuticals
|
$15M
|
BioAdvance Ventures, Birchmere Ventures |
Protez intends to use the proceeds from the financing to accelerate development of its lead compound SMP-601, an injectable antibiotic. |
|
OncoGenex Technologies
|
$12.8M
|
Ventures West, H.I.G. Ventures |
The money will be used for the development of the company's lead compound OGX-011 in multiple cancer indications and support the advancement of its second product candidate, OGX-427, into clinical development. |
|
Alder Biopharmaceuticals
|
$11.1M
|
Sevin Rosen Funds |
The money will be used to develop Alder's lead antibody therapeutic, broaden its product pipeline, and build on its proprietary antibody discovery and manufacturing technologies. |